Ultrasound scanning with contrast enhancement to assess disease activity in Crohn's disease

Contrast-enhanced ultrasound assessment of Crohn's disease activity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12609000323224

Enrollment

Registered

2009-05-21

Start date

2009-03-01

Completion date

2009-12-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of this study is to determine whether measurements obtained from an ultrasound scan of the bowel with the use of a contrast agent provides useful information on the disease activity of patients with Crohn's disease.

Interventions

Observational study - participants will receive up to two bolus intravenous injections of ultrasound contrast (perflutren lipid microsphere, each bolus approximately 0.75ml of contrast agent diluted to 5ml with normal saline) on each of the two visits. Contrast enhancement of the bowel wall will be observed for approximately 10 minutes post injection.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Patients with Crohn’s disease who are experiencing an exacerbation (Crohn’s disease activity index, CDAI >150) and who require a colonoscopy or flexible sigmoidoscopy

Exclusion criteria

Pregnant and lactating women, patients with abdominal surgery during the past 6 months, known right-to-left intracardiac shunts, unstable cardiac disease, pulmonary hypertension, severe chronic obstructive pulmonary disease, pulmonary vasculitis and hypersensitivity to ultrasound contrast agents.

Outcome results